Intercept Pharma

Intercept Pharmaceuticals, Inc., is a global biopharmaceutical company engaged in the development and commercialisation of innovative therapeutics to treat non-viral, progressive liver diseases with unmet medical needs and limited solutions. The company was founded in 2002, and operates in the US, Europe, and Canada. Intercept Pharmaceuticals, Inc. has its corporate headquarters in Hudson Yards, New York. The company's main product candidates include Ocaliva (obeticholic acid or OCA), which is a bile acid analogue, used for the treatment of primary biliary cholangitis (PBC). It is primarily used in patients who are in treatment for PBC and still have a high alkaline phosphatase (ALP) as the medication can effectively lower ALP in such patients. The firm is also expanding its pipeline to evaluate new indications for liver diseases with limited therapeutic options, with an emphasis on leveraging their team’s background in bile acid chemistry to discover and develop other potentially useful compounds. The firm employs around 500 people, and serves patients in more than 30 countries. It has international headquarters in London and, since 2018, has partnered with AOP Orphan Pharmaceuticals AG in Vienna, Austria, to provide access to Ocaliva across a number of European countries. The firm is listed on the NASDAQ under the ticker ICPT. Stay up-to-date on ICPT value changes here on eToro.